ian_hudson

New MHRA chief executive named

pharmafile | July 5, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MHRA, ian hudson 

The Department of Health has announced the appointment of Dr Ian Hudson as chief executive of the Medicines and Healthcare Products Regulatory Agency (MHRA).

Hudson is currently the MHRA’s Licensing director, responsible for the majority of medicines licensing activities. He is the UK delegate to the Committee on Human Medicinal Products (CHMP) at the European Medicines Agency and has been its vice-chairman since October 2012. He will take up the post in September when Sir Kent Woods steps down after ten years with the agency.

Lord Howe, Health Minister said: “I am delighted to welcome Dr Hudson to his new role. The MHRA carries out vital work to protect the health and well-being of people by ensuring medicines and medical devices work and are acceptably safe.

“Dr Hudson is used to working to the highest possible standards and maintaining the very toughest scrutiny over a fast-moving industry and I am confident he will find this role a deeply rewarding challenge.”

Hudson added: “I’m delighted to be appointed to the role of chief executive. The MHRA plays a critical role in ensuring that medicines and medical devices help people and are acceptably safe; we support research and development; and protect and promote the health of millions of people through our activities.

“Sir Kent has led the MHRA very effectively and has developed it into one of the leading medicines and medical devices regulators in the world. I am proud to have been selected to succeed him in the autumn.”

 

Related Content

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has …

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing …

Latest content